HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings

This article was originally published in The Tan Sheet

Executive Summary

CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.

You may also be interested in...



Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels

Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.

Mandatory Product Listing: Needed For US VMS Market, Not Mandatory In User Fee Bill – CRN

Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.

Misbranding Grades Coming For Compliant VMS Labeling If Found Missing From Proposed MPL

Under Senate legislation proposing mandatory listing with FDA for all supplements sold in US, a product labeled in compliance with all other agency regulations would be deemed misbranded if not registered for  proposed list.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS123714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel